Loading…
Qingdao firm that runs sales, marketing and distribution of branded medicines and supplements, including Dicare calcium, for brand owners.
Qingdao firm that runs sales, marketing and distribution of branded medicines and supplements, including Dicare calcium, for brand owners.
Is mainly paid to build and run brands rather than to make drugs, handling consumer education, doctor outreach, marketing and distribution for medicines and supplements such as the Dicare calcium line. Wholesale distribution and pharmacies add volume at lower returns, and it is deliberately trimming wholesale. Investments in innovative-drug developers are a newer thread.
Moat: narrow (distribution, brand). Hospital and pharmacy channel reach plus long-run consumer brands such as Dicare; depends on partners renewing brand rights.
Headquarters: Qingdao, China · Employees: 3,498
Size Qingdao Baheal Medical (301015.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.02B, the 1250th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥25.62 on 6 Nov 2026.
Performance Over six months the shares gained 3.9%, against -4.8% for the median peer and -16.4% for the China market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue fell 6.2% over the last twelve months (peer median +6.0%); the operating margin is 7.8% (peer median 13.7%).
Valuation It trades at 23.5× forward earnings against a peer median of 19.3× (9th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.4 points above its cost of capital (6.5% WACC).
Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥7.10B | CN¥7.47B | CN¥8.06B | CN¥8.22B | CN¥7.48B |
| Revenue growth | — | -7% | -2% | +10% | — |
| Gross profit | CN¥2.80B | CN¥2.71B | CN¥2.79B | CN¥2.66B | CN¥2.01B |
| EBITDA | n/a | CN¥854M | CN¥1.07B | CN¥1.13B | CN¥773M |
| Net income | CN¥238M | CN¥475M | CN¥692M | CN¥712M | CN¥507M |
| Free cash flow | CN¥296M | CN¥653M | CN¥518M | CN¥619M | CN¥204M |
| Capital expenditure | CN¥219M | CN¥289M | CN¥304M | CN¥185M | CN¥105M |
| Total debt | CN¥4.11B | CN¥3.86B | CN¥2.80B | CN¥1.80B | CN¥1.77B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Qingdao Baheal Medical 301015.SZ | $2.02B | +4% | -6% | 8% | 23.5× | 11.9% |
| Sinopharm 1099.HK | $6.83B | -4% | +3% | 3% | 6.3× | -8.1% |
| Shanghai Pharmaceuticals 601607.SS | $8.32B | -2% | +4% | 3% | 11.4× | -10.0% |
| Jointown Pharmaceutical 600998.SS | $3.96B | +1% | +9% | 2% | 11.7× | 0.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301015.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.2% | -0.8% | 10th lowest of 21 |
| 6-month return | +3.9% | -4.8% | 10th highest of 21 |
| Distance from 52-week high | -10.9% | -28.9% | 5th highest of 21 |
| Revenue growth (TTM) | -6.2% | +6.0% | 6th lowest of 21 |
| Operating margin | 7.8% | 13.7% | 7th lowest of 21 |
| Forward P/E | 23.5× | 19.3× | 9th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 11.9% | 3.7% | 8th most demanding of 18 |
| Growth delivered (Del g) | +5.0% | +8.0% | 6th lowest of 18 |
| Hurdle (Req g minus delivered) | +6.9 pp | -3.1 pp | 8th most demanding of 18 |
| ROIC minus cost of capital | +3.4 pp | -0.4 pp | 8th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Qingdao Baheal Medical 301015.SZ | China | $2.02B | +4% | -6% | 8% | 23.5× | 11.9% | +5.0% |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.02B | +7% | +5% | 22% | 15.9× | -4.8% | +10.6% |
| Grand Pharmaceutical 0512.HK | Hong Kong | $2.01B | -27% | +7% | 13% | 9.8× | 1.2% | +14.1% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.01B | +24% | +20% | 12% | 24.4× | 25.0% | +6.5% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $2.01B | -9% | -9% | 30% | 19.3× | 9.1% | +9.3% |
| Prestige Consumer Healthcare PBH | United States | $2.04B | -18% | -1% | 26% | 9.3× | -0.2% | +2.9% |
| BrightGene Bio-Medical Technology 688166.SS | China | $2.00B | -51% | +14% | 7% | 87.6× | 38.5% | +9.2% |
| United Laboratories International 3933.HK | Hong Kong | $2.00B | -19% | -13% | 5% | 14.5× | 3.7% | +7.8% |
| Jinyu Bio-Technology 600201.SS | China | $2.04B | -15% | +22% | 10% | 62.4× | 24.4% | -2.4% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.99B | -28% | -28% | -50% | 25.7× | 14.0% | -11.0% |
| Sino Biological 301047.SZ | China | $1.98B | +50% | +20% | 17% | 63.8× | 36.8% | -15.1% |
| Shilpa Medicare SHILPAMED.NS | India | $1.95B | +113% | +28% | 21% | 62.1× | n/a | n/a |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.95B | 0% | +13% | 27% | 13.0× | -0.5% | +16.7% |
| Harbin Pharmaceutical 600664.SS | China | $2.10B | +55% | +2% | 5% | 23.1× | -2.9% | +8.2% |
| Zymeworks ZYME | United States | $2.10B | +24% | -70% | -419% | 12.0× | n/a | n/a |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.94B | -12% | +11% | 6% | 45.0× | n/a | n/a |
| Dermapharm DMP.DE | Germany | $2.11B | -25% | 0% | 22% | 14.5× | -3.8% | +8.0% |
| Harmony Biosciences HRMY | United States | $1.93B | +7% | +20% | 22% | 8.6× | -10.9% | +40.3% |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.12B | +17% | -1% | 14% | 17.5× | 2.4% | +15.7% |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $2.12B | -41% | -18% | 9% | n/a | 37.9% | +0.9% |
| Alivus Life Sciences ALIVUS.NS | India | $1.92B | +32% | +8% | 31% | 24.4× | 20.4% | +6.2% |